Radiation dose has been reported to be an important determinant

Size: px
Start display at page:

Download "Radiation dose has been reported to be an important determinant"

Transcription

1 538 The Relationship of Increasing Radiotherapy Dose to Reduced Distant Metastases and Mortality in Men with Prostate Cancer Rojymon Jacob, M.D. 1 Alexandra L. Hanlon, Ph.D. 2 Eric M. Horwitz, M.D. 1 Benjamin Movsas, M.D. 1 Robert G. Uzzo, M.D. 3 Alan Pollack, M.D., Ph.D. 1 1 Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 2 Department of Biostatistics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 3 Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. BACKGROUND. The association of increasing radiotherapy (RT) dose with reduced biochemical failure (BF) is accepted widely. However, there is little direct evidence that dose escalation has an impact on distant metastasis (DM) or overall mortality (OM). These associations were examined in the current study. METHODS. The outcome of 835 patients who were treated at the Fox Chase Cancer Center (Philadelphia, PA) between 1989 and 1997 using 3-dimensional, conformal RT alone (median dose, 74 Gray [Gy]) was analyzed. Stepwise multivariate Cox proportional hazards regression analyses (MVAs) were performed with RT dose included as a covariate along with log-transformed initial pretreatment PSA level, Gleason score, palpation T status, age, and year of treatment (YOT), where indicated. To minimize the effect of YOT, an analysis was performed on a subgroup of 363 patients who were treated prior to RESULTS. With a median follow-up of 64 months, there were 220 PSA failures, 44 distant metastases, and 162 deaths. In MVA, RT dose (as a continuous variable) was a significant predictor for BF, DM, and OM. When YOT was included as a covariate, it was related strongly to all endpoints, and the correlations of RT dose with DM and OM were lost. When the effect of YOT was minimized by limiting the MVA to patients who were treated prior to 1994, RT dose again emerged as a significant predictor of DM. CONCLUSIONS. Escalation of RT dose reduced the rates of BF, DM, and OM significantly in patients with prostate cancer. The inclusion of YOT had a pronounced effect on these correlations that may confound interpretation. Cancer 2004;100: American Cancer Society. Supported in part by Grant CA from the National Cancer Institute and the Department of Defense and by United States Army Medical Research Grant PC Address for reprints: Alan Pollack, M.D., Ph.D., Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA ; Fax: (215) ; a_pollack@fccc.edu The views expressed herein are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute or the United States Department of Defense. Received July 22, 2003; revision received October 1, 2003; accepted October 20, KEYWORDS: prostate carcinoma, radiotherapy, dose escalation, metastasis, mortality. Radiation dose has been reported to be an important determinant of outcome in prostate cancer patients treated with radiotherapy (RT) in the prostate-specific antigen (PSA) era. 1 4 However, the effect of RT dose has been manifest primarily using biochemical failure (BF) as the endpoint. Although the pattern of a rising serum PSA level is regarded as an early predictor of distant metastasis (DM), 3,5 8 the relationship of BF to overall mortality (OM) is less well established Moreover, direct evidence that RT dose reduces DM or OM has not been conclusive. 3,12 17 In the current report, the association of RT dose to DM and OM was examined in a population of men with prostate carcinoma who were treated relatively uniformly with three-dimensional (3D)-conformal RT. Because, over the period of the study ( ), stage mign and Gleason score shift occurred, both of which 2003 American Cancer Society DOI /cncr.11927

2 Radiation Dose Escalation and Mortality/Jacob et al. 539 TABLE 1 Distribution of Patients by Gleason Score and T Stage after Subdivision by Initial Pretreatment Prostate-Specific Antigen Level ipsa Gleason score T stage T1/T2a b 10 ng/ml ng/ml Total ipsa: initial pretreatment prostate-specific antigen level. Total complicate retrospective analyses of treatment changes over time, the year of treatment (YOT) was included as a covariate. The effect of the inclusion of YOT on the relationship of RT dose to DM and OM was investigated. MATERIALS AND METHODS Patient Characteristics A total of 835 patients treated consecutively between April, 1989 and November, 1997 using 3D-conformal RT comprised the study cohort. Pathologic grading of diagnostic biopsy specimens was performed at Fox Chase Cancer Center (Philadelphia, PA). An initial pretreatment PSA (ipsa) level was available from all patients, and the median ipsa level was 9.0 ng/ml (range, ng/ml). The median age of the study population was 69 years (range, years). Table 1 shows palpation T stage and Gleason score subdivided by ipsa level. The majority of patients (n 470) had an ipsa level 10 ng/ml. Three hundred seventy-one patients had an ipsa level of 10 ng/ml and a Gleason score between 2 and 6. Treatment Patients were immobilized in a custom-made alphacradle cast, supine, before computed tomographicsimulation. The target volumes and technique of RT planning have been described previously. 25,26 In general, a four-field technique using megavoltage irradiation was used. For favorable-risk patients with a T1/T2 classification and a Gleason score of 2 6, only the prostate was treated. For the remaining intermediate- to high-risk patients, the prostate and periprostatic tissues were treated to Gray (Gy), then a reduction was made to the prostate and seminal vesicles. A 1-cm planning target volume (PTV) margin was placed around the clinical target volume structures, and a 0.5-cm margin around the PTV typically was placed for penumbra. The median ICRU reference point dose was 74 Gy, with a range of Gy (99% of patients received 68 Gy), with 5% variation across the PTV. None of the patients received neoadjuvant or adjuvant androgen deprivation as part of their treatment. Follow-Up and Endpoints Patients typically were seen at 3 months and then every 6 12 months. PSA values were obtained at 3 months and every 6 12 months thereafter. Radiologic evaluation, as part of the work-up for metastasis, was performed when indicated based on clinical assessment or PSA values. BF, DM, and OM were the endpoints for the study. The study population had a median follow-up of 64 months (range, months). BF was defined according to the American Society of Therapeutic Radiology and Oncology (ASTRO) criteria, which include three consecutive rises in serum levels of PSA after reaching a nadir. 27 DM was defined as radiologic confirmation of hematogenous metastasis. Statistical Analysis Estimates of BF, DM, and OM were calculated using the Kaplan Meier product-limit method. 28 Univariate comparisons of outcome were accomplished using the log-rank test. 29 Multivariate analysis (MVA) using stepwise Cox proportional hazards regression models was used to evaluate predictors of outcome. 30 RT dose was used as a continuous variable in MVA and was dichotomized at 76 Gy for univariate comparisons. The 76 Gy cutoff point was chosen because most retrospective series have identified the greatest effects from doses at or above this level. 2,3,26,31 Other covariates for MVA included log-transformed ipsa level (continuous), T stage (T1/T2a,b vs. ), Gleason score (2 6 vs. 7 10), age (continuous), and YOT (continuous). Log-transformed ipsa(log[ipsa]) values were used because the log-transformation resulted in a Gaussian distribution. 6 To minimize the potential confounding effect of YOT as a covariate, the statistical analysis was repeated on the subgroup of 363 patients who were treated between 1989 and 1993; this population had mature follow-up (median, 92 months; range, months) and was treated prior to an observed shift in Gleason scoring by pathologists that we determined had occurred after RESULTS There were 220 BFs, 44 DMs, and 162 deaths (OM) within the study follow-up period. Kaplan Meier s of BF, DM, and OM at 8 years are shown in Table 2. On univariate analysis, Gleason score, ipsa level, and T stage were significant correlates of BF, DM, and OM. Doses of RT 76 Gy were associated with reduced rates of BF and OM. RT dose was not

3 540 CANCER February 1, 2004 / Volume 100 / Number 3 TABLE 2 Relationship of Various Prognostic Factors to 8-Year Kaplan Meier Estimates of Biochemical Failure, Distant Metastasis, and Overall Mortality No. of patients BF (%) DM (%) OM (%) Gleason score a 16 a 38 a T stage T1/T2a b a 16 a 37 a ipsa (ng/ml) a 15 a 33 a RT dose (Gy) a 6 b 22 a BF: biochemical failure; DM: distant metastases; OM: overall mortality; ipsa; initial pretreatment prostate-specific antigen level; RT: radiotherapy; Gy: Gray. a P b P TABLE 3 Multivariate Cox Proportional s Analysis using Biochemical Failure as the Endpoint a RT dose Continuous Log(iPSA) Continuous Gleason score 2 6 vs T stage T1/T2a b vs RT: radiotherapy; Log(iPSA): log-transformed initial prostate specific antigen level. a Two hundred twenty of 835 patients in the analysis experienced biochemical failure. related to DM in univariate analysis (P 0.17). For patients with tumors T3 and Gleason scores 7, there was a trend toward a lower DM rate with doses 76 Gy (P 0.08). The lack of association between RT dose and DM in univariate analysis may have been caused by the cut-point that was chosen (76 Gy was used because previous studies have indicated that this is an important threshold level) and by an unequal distribution of other factors. MVAs that incorporated RT dose as a continuous variable were performed to address these issues. Tables 3 5 show the results of the MVAs without YOT included as a covariate. RT dose was significantly associated with BF, DM, and OM. The higher the RT dose, the lower the risk of BF, DM, or OM. The other significant covariates were log(ipsa), T stage, and TABLE 4 Multivariate Cox Proportional s Analysis using Distant Metastasis as the Endpoint a RT dose Continuous Log(iPSA) Continuous Gleason score 2 6 vs T stage T1/T2a b vs RT: radiotherapy; Log(iPSA): log-transformed initial prostate-specific antigen level. a Forty-four of 835 patients had distant metastasis. TABLE 5 Multivariate Cox Proportional s Analysis using Overall Mortality as the Endpoint a RT dose Continuous Gleason score 2 6 vs T stage T1/T2a b vs Age Continuous RT: radiotherapy. a There were 162 deaths overall among the 835 patients in the analysis. TABLE 6 Multivariate Cox Proportional s Analysis using Distant Metastasis as the Endpoint and Including the Year of Treatment as a Covariate a Gleason score 2 6 vs T stage T1/T2a b vs YOT Ordinal YOT: year of treatment. a Forty-four of 835 patients had distant metastasis. Gleason score. Age was related significantly to OM, but not to BF or DM. When YOT was included in the MVAs as a continuous variable, it was associated significantly with BF (P ), DM (P ), and OM (P ). RT dose remained related independently to BF (not shown) but not to DM (Table 6) or OM (Table 7). Log(iPSA) continued to be related significantly to BF but not to DM or OM. Because YOT was significantly related to RT dose (P analysis of variance) and, therefore, could

4 Radiation Dose Escalation and Mortality/Jacob et al. 541 TABLE 7 Multivariate Cox Proportional s Analysis using Overall Mortality as the Endpoint and Including the Year of Treatment as a Covariate a Gleason score 2 6 vs T stage T1/T2a b vs YOT Continuous Age Continuous YOT: year of treatment. a There were 162 deaths overall among the 835 patients in the analysis. TABLE 8 Multivariate Cox Proportional s Analysis using Distant Metastasis as the Endpoint in the Subset of 363 Patients who were Treated before 1994 a RT dose Continuous Gleason score 2 6 vs T status T1/T2a b vs RT: radiotherapy. a Twenty-eight of the 363 patients had distant metastasis. confound the association of RT dose to patient outcome, a subgroup of patients treated between 1989 and 1993 (n 363) was investigated. In this subgroup, there were 132 BFs, 28 DMs, and 116 deaths (OM). Median follow-up was 92 months. In MVA, RT dose, Gleason score 7 10, and T3 category were related significantly to DM (Table 8); YOT was not significant and was not included in the final model. The only significant predictor for OM was age. DISCUSSION Many retrospective and prospective studies have confirmed a reduction in BF as a consequence of increasing RT dose. 1 4 However, there is little evidence of the impact of RT dose on DM and OM. In the University of Texas M. D. Anderson Cancer Center s randomized radiation dose escalation prostate carcinoma trial, which compared a 70 Gy to 78 Gy, 3 the DM rate was lower for patients with a PSA level 10 ng/ml who were treated with 78 Gy (2% vs. 12% at 6 years; P 0.056). No relation between RT dose and OM was seen in that study, because there were few deaths attributable to prostate carcinoma. Also, in a matched-pair analysis that compared 74 Gy 74 Gy by Hanks et al., 15 RT dose was associated significantly with DM and cause-specific death for patients who were matched for ipsa, Gleason score, and T stage. Kestin et al. 16 also did a matched-pair analysis and found that higher biologic RT doses were associated with reduced OM; however, those authors did not find any relation of dose with DM or cause-specific death. In one of the few studies wherein MVA was performed, Valicenti et al. 17 found that RT dose was an independent predictor of cause-specific death and OM for patients who had Gleason scores of That analysis involved patients who were treated in Radiation Therapy Oncology Trials in the pre-psa era; and, although there was a range of doses used, 87% of patients were treated with conventional doses 70.2 Gy. No adjustment was made for time-related changes, such as stage mign or differences in follow-up. To our knowledge, no previous PSA-era multivariate study of patients who were treated mainly with conventional or greater RT doses has investigated the impact of dose on DM or OM and included a covariate (e.g., YOT) to account for such time-related concerns. The data shown here reveal a strong association between increasing RT dose and reduced DM and OM. Although the MVAs documented that RT dose was independent of T stage, Gleason score, and ipsa, there are concerns about reliability. Over the course of the study ( ), there were notable changes in patient attributes. The use of PSA and new or improved imaging modalities in screening (e.g., ultrasound and endorectal coil magnetic resonance imaging) and transrectal, ultrasound-guided, sextant or greater biopsies contributed to earlier diagnosis. These features, combined with changes in the American Joint Committee on Cancer staging system, such as the inclusion of imaging and biopsy findings, have resulted in stage mign A prostate cancer patient with T2b disease today is not the same as a patient with T2b disease 5 10 years ago. Another, perhaps even more significant factor that obscures retrospective studies is the shift in Gleason scoring that has occurred over the study period Recently, Chism et al. 32 found that pathologists consistently are assigning higher Gleason scores in diagnostic prostate biopsy specimens today compared with the scores assigned prior to Thus, a tumor may have been assigned a Gleason score of 6 in the early 1990s and a score of 7 in the late 1990s. Such time-related changes would improve the outcome of patients with Gleason 6 and Gleason 7 disease artificially over time. Distinguishing between the effect of RT dose, which also was altered over time, and follow-up differences (patients who received higher RT doses gen-

5 542 CANCER February 1, 2004 / Volume 100 / Number 3 erally were treated more recently), 33 stage mign, Gleason score shift, and possibly other factors affecting patient outcome is not possible without the inclusion of a covariate that adjusts for these changes. This is the reason for the inclusion of YOT as a covariate. The influence of the time-dependent changes that occurred in follow-up, stage classification, and Gleason scoring should be negated by YOT; however, because RT dose is associated significantly with YOT, any impact of RT dose on outcome also would be blunted. Indeed, when YOT was included in the MVAs, RT dose no longer was associated with DM or OM. There still was a strong relationship between RT dose and BF. One way to limit the influence of time-related factors is to perform the MVAs on patients who were treated over a shortened time span. When only patients treated between 1989 and 1993, inclusive, were considered, it was found that RT dose was related to DM. Under those conditions, YOT was not significant in MVA and was not included in the final model (Table 8). These data provide much more convincing evidence that RT dose is effective at reducing DM. The inability to document an association between RT dose and OM in this cohort probably was related to the limited number of patients; death due to intercurrent disease in patients with prostate cancer is common, necessitating large numbers of patients when OM is used as the endpoint. In summary, increasing RT dose improved outcomes in patients with clinically localized prostate carcinoma. The association with BF is undisputed; however, the association with DM and OM has been less certain. Our data show that RT dose also is related significantly to DM. We were only able to show an association between RT dose and OM without correcting for time-related changes (exclusion of YOT as a covariate); a larger patient cohort will be needed to establish this association more conclusively. REFERENCES 1. Lyons J, Kupelian P, Mohan D, Reddy C, Klein EA. Importance of high radiation doses (72 Gy or greater) in the treatment of Stage T1 T3 adenocarcinoma of the prostate. Urology. 2000;55: Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166: Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson Phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53: Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8 12 years follow-up. Int J Radiat Oncol Biol Phys. 2002;54: Zagars GK, Pollack A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer. 1993;72: Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 1994;74: Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 1997;44: Pound C, Partin A, Eisenberger M, Chan D, Pearson J, Walsh P. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281: Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specificantigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48: Kwan W, Pickles T. In regard to Kupelian et al.: impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. IJROBP 2002;52: Int J Radiat Oncol Biol Phys. 2002;54: ; author reply, Kupelian PA, Buchsbaum JC, Patel C, et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys. 2002;52: Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32: Fiveash J, Hanks G, Roach M, et al. 3D conformal radiation therapy (3D CRT) for high grade prostate cancer: a multiinstitutional review. Int J Radiat Oncol Biol Phys. 2000;47: Magrini SM, Cellai E, Pertici M, et al. Radical radiotherapy of localised prostate cancer: the relationship between radiation dose and survival. Cancer Radiother. 1998;2: Hanks G, Hanlon A, Pinover W, Horwitz E, Schultheiss T. Survival advantage for prostate cancer patients treated with high dose 3D conformal radiation. Cancer J Sci Am. 1999;5: Kestin LL, Martinez AA, Stromberg JS, et al. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol. 2000;18: Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology trials. J Clin Oncol. 2000;18: Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 1998;73: Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer Part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91: Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage mign. J Clin Oncol. 1999;17:

6 Radiation Dose Escalation and Mortality/Jacob et al Ung JO, Richie JP, Chen MH, Renshaw AA, D Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology. 2002;60: Schellhammer PF, Moriarty R, Bostwick D, Kuban D. Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Urology. 2000; 56: Smith EB, Frierson HF Jr., Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer. 2002;94: Chism DB, Hanlon AL, Troncoso P, Horwitz EM, Pollack A. Impact on outcome of the Gleason score shift. Int J Radiat Oncol Biol Phys. 2002;54: Hanks GE, Hanlon AL, Schultheiss TE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization and future directions. Int J Radiat Oncol Biol Phys. 1998;41: Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001;92: Cox J, Grignon D, Kaplan R, Parsons J, Schellhammer P. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: Mantel N. Evaluation of survival data and two new rank order statistics arising in its considen. Cancer Chemother Rep. 1966;50: Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34: Pollack A, Smith L, von Eschenbach A. External beam radiotherapy dose-response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys. 2000;48: Chism D, Hanlon AL, Troncoso P, Horwitz EM, Pollack A. The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys. 2002;56: Vicini F, Kestin L, Martinez A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:

The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer

The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer 55 The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer Matthew C. Abramowitz, MD 1 Tiaynu Li, MA 2 Mark K. Buyyounouski, MD 1 Eric Ross, PhD 2 Robert

More information

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative

More information

Vol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10

Vol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10 25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04

More information

Supported by M. D. Anderson Cancer Center physician investigator funds. We thank Gerald E. Hanks, MD, for help and guidance with this project.

Supported by M. D. Anderson Cancer Center physician investigator funds. We thank Gerald E. Hanks, MD, for help and guidance with this project. 1496 Biochemical and Clinical Significance of the Posttreatment Prostate-Specific Antigen Bounce for Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone A Multiinstitutional Pooled

More information

Radiation treatment in prostate cancer : balancing between tumor control and toxicity Heemsbergen, W.D.

Radiation treatment in prostate cancer : balancing between tumor control and toxicity Heemsbergen, W.D. UvA-DARE (Digital Academic Repository) Radiation treatment in prostate cancer : balancing between tumor control and toxicity Heemsbergen, W.D. Link to publication Citation for published version (APA):

More information

Project approved by the Fondo de investigaciones Socio Sanitarias (FISS). Resolution dated June 8, Official State Gazette: June 17, 2004.

Project approved by the Fondo de investigaciones Socio Sanitarias (FISS). Resolution dated June 8, Official State Gazette: June 17, 2004. Edition No. 01 Phase III randomized and multicenter trial of adjuvant androgen deprivation combined with high-dose 3-dimensional conformal radiotherapy in intermediate- or high-risk localized prostate

More information

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER

HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER 0022-5347/01/1663-0876/0 THE JOURNAL OF UROLOGY Vol. 166, 876 881, September 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED

More information

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series

Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,

More information

Treatment Failure After Primary and Salvage Therapy for Prostate Cancer

Treatment Failure After Primary and Salvage Therapy for Prostate Cancer 307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2

More information

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA

More information

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes

Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,

More information

Biochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy

Biochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir October 2015, Volume: 7, Issue: 6, Pages: 1330-1335, DOI: 10.14661/1330 Biochemical progression-free survival in localized prostate cancer

More information

Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients

Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend

More information

doi: /s (03) CLINICAL INVESTIGATION

doi: /s (03) CLINICAL INVESTIGATION doi:10.1016/s0360-3016(03)01746-2 Int. J. Radiation Oncology Biol. Phys., Vol. 58, No. 4, pp. 1048 1055, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front

More information

diagnosed by transrectal needle biopsy who completed 3DCRT alone be- Center, Philadelphia, Pennsylvania.

diagnosed by transrectal needle biopsy who completed 3DCRT alone be- Center, Philadelphia, Pennsylvania. 75 Evidence of Increased Failure in the Treatment of Prostate Carcinoma Patients Who Have Perineural Invasion Treated with Three-Dimensional Conformal Radiation Therapy Steven R. Bonin, M.D. 1 BACKGROUND.

More information

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy

More information

When radical prostatectomy is not enough: The evolving role of postoperative

When radical prostatectomy is not enough: The evolving role of postoperative When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer

More information

Prognostic value of the Gleason score in prostate cancer

Prognostic value of the Gleason score in prostate cancer BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska

More information

Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer

Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer Japanese Journal of Clinical Oncology Advance Access published May 30, 2006 Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer Jun Shimazaki 1, Koichiro Akakura 1, Hiroyoshi Suzuki 1,

More information

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy

Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical

More information

in 32%, T2c in 16% and T3 in 2% of patients.

in 32%, T2c in 16% and T3 in 2% of patients. BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson

More information

Jure Murgic 1, Matthew H Stenmark 1, Schuyler Halverson 1, Kevin Blas 1, Felix Y Feng 1,2 and Daniel A Hamstra 1,3*

Jure Murgic 1, Matthew H Stenmark 1, Schuyler Halverson 1, Kevin Blas 1, Felix Y Feng 1,2 and Daniel A Hamstra 1,3* Murgic et al. Radiation Oncology 2012, 7:127 RESEARCH Open Access The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for

More information

JAMA. 1998;280:

JAMA. 1998;280: Original Contributions Biochemical Outcome After Radical Prostatectomy, Radiation Therapy, or Interstitial for Clinically Localized Prostate Cancer Anthony V. D Amico, MD, PhD; Richard Whittington, MD;

More information

RADICAL PROSTATECTOMY IS ONE

RADICAL PROSTATECTOMY IS ONE ORIGINAL CONTRIBUTION Risk of Prostate Cancer Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy Stephen J. Freedland, MD Elizabeth B. Humphreys, BS Leslie A. Mangold, MS Mario

More information

PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up

PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Original article Original articles PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Roman Makarewicz, MD, PhD, Prof., Andrzej

More information

Predictive factors of late biochemical recurrence after radical prostatectomy

Predictive factors of late biochemical recurrence after radical prostatectomy JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original

More information

Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy

Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and

More information

Introduction ORIGINAL RESEARCH

Introduction ORIGINAL RESEARCH Cancer Medicine ORIGINAL RESEARCH Open Access Prostate- specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low- dose- rate brachytherapy

More information

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION VOLUME 23 NUMBER 28 OCTOBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prostate Cancer Specific Mortality After Radical Prostatectomy or Radiation Therapy Ping Zhou,

More information

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1. NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low

More information

Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer

Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer ONCOLOGY LETTERS 10: 255-259, 2015 Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer MITSURU OKUBO, HIDETUGU NAKAYAMA, TOMOHIRO ITONAGA, YU TAJIMA, SACHIKA

More information

Radiation Therapy After Radical Prostatectomy

Radiation Therapy After Radical Prostatectomy Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg

More information

UPDATE OF DUTCH MULTICENTER DOSE-ESCALATION TRIAL OF RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER

UPDATE OF DUTCH MULTICENTER DOSE-ESCALATION TRIAL OF RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER doi:1.116/j.ijrobp.28.2.73 Int. J. Radiation Oncology Biol. Phys., Vol. 72, o. 4, pp. 98 988, 28 Copyright Ó 28 Elsevier Inc. Printed in the USA. All rights reserved 36-316/8/$ see front matter CLIICAL

More information

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience

Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,

More information

Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series

Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka

More information

BJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent

BJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent 21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for

More information

Department of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt.

Department of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt. Original article Res. Oncol. Vol. 12, No. 1, Jun. 2016:10-14 Dosimetric comparison of 3D conformal conventional radiotherapy versus intensity-modulated radiation therapy both in conventional and high dose

More information

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon

More information

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations

2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations 2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes

More information

The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials

The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials British Journal of Cancer (2004) 90, 950 954 All rights reserved 0007 0920/04 $25.00 www.bjcancer.com Minireview The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective

More information

concordance indices were calculated for the entire model and subsequently for each risk group.

concordance indices were calculated for the entire model and subsequently for each risk group. ; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai

More information

TREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME

TREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME ADULT UROLOGY TREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME VIBHA BHATNAGAR, SUSAN T. STEWART, WILLIAM W. BONNEY, AND ROBERT M. KAPLAN ABSTRACT

More information

failure (FBF) rates were calculated using the Phoenix definition.

failure (FBF) rates were calculated using the Phoenix definition. . JOURNAL COMPILATION 2009 BJU INTERNATIONAL Urological Oncology GLEASON SCORES 8 10 PROSTATE CANCER TREATED WITH TRIMODAL THERAPY STOCK et al. BJUI BJU INTERNATIONAL Outcomes for patients with high-grade

More information

Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer

Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer Original Article Radiat Oncol J 205;33():2-28 http://dx.doi.org/0.3857/roj.205.33..2 pissn 2234-900 eissn 2234-356 Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation

More information

SRO Tutorial: Prostate Cancer Clinics

SRO Tutorial: Prostate Cancer Clinics SRO Tutorial: Prostate Cancer Clinics May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible, and

More information

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION VOLUME 26 NUMBER 4 FEBRUARY 1 28 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate

More information

estimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.

estimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c. . JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical

More information

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM

CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN

More information

Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice

Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio

More information

Corey C Foster 1, William C Jackson 1, Benjamin C Foster 1, Skyler B Johnson 1, Felix Y Feng 1 and Daniel A Hamstra 1,2*

Corey C Foster 1, William C Jackson 1, Benjamin C Foster 1, Skyler B Johnson 1, Felix Y Feng 1 and Daniel A Hamstra 1,2* Foster et al. Radiation Oncology 2014, 9:245 RESEARCH Open Access Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical

More information

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors 2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.

More information

Updated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy for Locally and Locally Advanced

Updated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy for Locally and Locally Advanced Clinical Urology High-Dose Rate Brachytherapy for Prostate Cancer International Braz J Urol Vol. 34 (3): 293-301, May - June, 2008 Updated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy

More information

journal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract

journal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,

More information

Radical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer

Radical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation

More information

Christine M. Fisher, MD

Christine M. Fisher, MD Prostate biopsy upgrading and its implications on treatment modality and outcomes in men treated with radical prostatectomy or permanent seed implantation at UT M.D. Anderson Cancer Center, 2000-2001 By

More information

doi: /j.ijrobp CLINICAL INVESTIGATION

doi: /j.ijrobp CLINICAL INVESTIGATION CME doi:10.1016/j.ijrobp.2010.07.2004 Int. J. Radiation Oncology Biol. Phys., Vol. 81, No. 5, pp. 1293 1301, 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see

More information

Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center

Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,

More information

Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan

Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan KATSUMASA NAKAMURA 1, TERUKI TESHIMA 2, YUTAKA TAKAHASHI 2, ATSUSHI IMAI 3, MASAHIKO KOIZUMI 4, NORIO MITSUHASHI 5, YOSHIYUKI SHIOYAMA

More information

Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy

Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.

More information

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE

VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA

More information

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008 Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators

More information

Original Article. Cancer September 15,

Original Article. Cancer September 15, Gleason Pattern 5 Is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy William

More information

Lewis Garvey Smith III, MD Reference List

Lewis Garvey Smith III, MD Reference List Journal D'Souza WD, Lee HK, Palmer MB, Smith LG, Pollack A. Is intraoperative nomogram-based overplanning of prostate implants necessary? Int J Radiat.Oncol.Biol.Phys. 56[2], 462-467. 2003 Rosser CJ, Chichakli

More information

Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer

Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer Review Article [1] February 01, 2004 By David C. Beyer, MD [2] The options available for patients with recurrent prostate cancer

More information

ORIGINAL INVESTIGATION. Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. having prostate cancer, assessment

ORIGINAL INVESTIGATION. Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. having prostate cancer, assessment ORIGINAL INVESTIGATION Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans Edward M. Uchio, MD; Mihaela Aslan, PhD; Carolyn K. Wells, MPH; Juan Calderone, MD; John Concato, MD, MS, MPH

More information

Information Content of Five Nomograms for Outcomes in Prostate Cancer

Information Content of Five Nomograms for Outcomes in Prostate Cancer Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:

More information

Early outcomes of active surveillance for localized prostate cancer

Early outcomes of active surveillance for localized prostate cancer Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,

More information

The Use of Conformal Radiotherapy and the Selection of Radiation Dose in T1 or T2 Prostate Cancer

The Use of Conformal Radiotherapy and the Selection of Radiation Dose in T1 or T2 Prostate Cancer Evidence-based Series 3-11 EDUCATION AND INFORMATION 2011 The Use of Conformal Radiotherapy and the Selection of Radiation Dose in T1 or T2 Prostate Cancer Members of the Genitourinary Cancer Disease Site

More information

Michelle S Ludwig 1*, Deborah A Kuban 2, Xianglin L Du 4, David S Lopez 4, Jose-Miguel Yamal 5 and Sara S Strom 3

Michelle S Ludwig 1*, Deborah A Kuban 2, Xianglin L Du 4, David S Lopez 4, Jose-Miguel Yamal 5 and Sara S Strom 3 Ludwig et al. BMC Cancer (2015) 15:190 DOI 10.1186/s12885-015-1180-6 RESEARCH ARTICLE Open Access The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk

More information

PSA is rising: What to do? After curative intended radiotherapy: More local options?

PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung

More information

Radiation Dose Escalation for Localized Prostate Cancer

Radiation Dose Escalation for Localized Prostate Cancer Radiation Dose Escalation for Localized Prostate Cancer Intensity-Modulated Radiotherapy Versus Permanent Transperineal Brachytherapy William W. Wong, MD 1 ; Sujay A. Vora, MD 1 ; Steven E. Schild, MD

More information

NIH Public Access Author Manuscript Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2012 June 1.

NIH Public Access Author Manuscript Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2012 June 1. NIH Public Access Author Manuscript Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 June 1; 80(2): 445 452. doi:10.1016/j.ijrobp.2010.02.034. Impact of ultrahigh baseline PSA levels

More information

Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence

Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on

More information

New Technologies for the Radiotherapy of Prostate Cancer

New Technologies for the Radiotherapy of Prostate Cancer Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the

More information

MONA V. SANGHANI, DELRAY SCHULTZ, CLARE M. TEMPANY, DAVID TITELBAUM, ANDREW A. RENSHAW, MARIAN LOFFREDO, KERRI COTE, BETH MCMAHON,

MONA V. SANGHANI, DELRAY SCHULTZ, CLARE M. TEMPANY, DAVID TITELBAUM, ANDREW A. RENSHAW, MARIAN LOFFREDO, KERRI COTE, BETH MCMAHON, ADULT UROLOGY QUANTIFYING THE CHANGE IN ENDORECTAL MAGNETIC RESONANCE IMAGING-DEFINED TUMOR VOLUME DURING NEOADJUVANT ANDROGEN SUPPRESSION THERAPY IN PATIENTS WITH PROSTATE CANCER MONA V. SANGHANI, DELRAY

More information

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population

Evaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after

More information

A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer

A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer ORIGINAL RESEARCH A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer Daniel Taussky, MD; 1 Véronique Ouellet, MD; 2 Guila Delouya,

More information

PROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive

PROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive Prostate-Specific Antigen Doubling Times Are Similar in Patients With Recurrence After Radical Prostatectomy or Radiotherapy: A Novel Analysis By Bryan D. Leibman, Ozdal Dillioglugil, Peter T. Scardino,

More information

Overview of Radiotherapy for Clinically Localized Prostate Cancer

Overview of Radiotherapy for Clinically Localized Prostate Cancer Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive

More information

11. Prostate Cancer. Introduction

11. Prostate Cancer. Introduction 11. Prostate Cancer Introduction Prostate cancer is a major health problem, being the most common male cancer in Western countries. The steep increase in incidence is mainly due to increased public awareness

More information

Prostate Cancer: 2010 Guidelines Update

Prostate Cancer: 2010 Guidelines Update Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer

More information

DNA PLOIDY has been investigated as a potential prognostic

DNA PLOIDY has been investigated as a potential prognostic Prostate Cancer DNA Ploidy and Response to Salvage Hormone Therapy After Radiotherapy With or Without Short-Term Total Androgen Blockade: An Analysis of RTOG 8610 By A. Pollack, D.J. Grignon, K.H. Heydon,

More information

Journal of American Science 2018;14(1)

Journal of American Science 2018;14(1) Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,

More information

Prostate Cancer in comparison to Radiotherapy alone:

Prostate Cancer in comparison to Radiotherapy alone: Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +

More information

TITLE: Hierarchical Nonlinear Mixed Effects Modeling: Defining Post-Radiation Therapy Relapse in Prostate Cancer Patients

TITLE: Hierarchical Nonlinear Mixed Effects Modeling: Defining Post-Radiation Therapy Relapse in Prostate Cancer Patients AD Award Number: DAMD17-01-1-0056 TITLE: Hierarchical Nonlinear Mixed Effects Modeling: Defining Post-Radiation Therapy Relapse in Prostate Cancer Patients PRINCIPAL INVESTIGATOR: Alexandra L. Hanlon,

More information

Pathology Review for Patients with Prostate Cancer Referred to the SCCA Proton Center

Pathology Review for Patients with Prostate Cancer Referred to the SCCA Proton Center Pathology Review for Patients with Prostate Cancer Referred to the SCCA Proton Center George E. Laramore, PhD, MD; Jing Zeng, MD; Li-Ming Christine Fang, MD; Jay J. Liao, MD; Kenneth J. Russell, MD Department

More information

Introduction. Original Article

Introduction. Original Article bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after

More information

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical

More information

doi: /j.ijrobp CLINICAL INVESTIGATION

doi: /j.ijrobp CLINICAL INVESTIGATION doi:10.1016/j.ijrobp.2006.04.029 Int. J. Radiation Oncology Biol. Phys., Vol. 65, No. 4, pp. 965 974, 2006 Copyright 2006 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/06/$ see front

More information

TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer

TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer AD Award Number: W81XWH-04-1-0769 TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer PRINCIPAL INVESTIGATOR: Richard K. Valicenti,

More information

Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy

Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory

More information

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD

Understanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics

More information

Genitourinary Cancer. When Prostate Brachytherapy Fails: A Case Report and Discussion. The Oncologist 2005;10:

Genitourinary Cancer. When Prostate Brachytherapy Fails: A Case Report and Discussion. The Oncologist 2005;10: This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Genitourinary Cancer When Prostate Brachytherapy Fails: A Case

More information

DOSE ESCALATION USING CONFORMAL HIGH-DOSE-RATE BRACHYTHERAPY IMPROVES OUTCOME IN UNFAVORABLE PROSTATE CANCER

DOSE ESCALATION USING CONFORMAL HIGH-DOSE-RATE BRACHYTHERAPY IMPROVES OUTCOME IN UNFAVORABLE PROSTATE CANCER PII S0360-3016(02)02733-5 Int. J. Radiation Oncology Biol. Phys., Vol. 53, No. 2, pp. 316 327, 2002 Copyright 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/02/$ see front

More information

Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK

Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK Peter D. Dickinson*, Jahangeer Malik, Paula Mandall*, Ric Swindell*, David Bottomley,

More information

Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer

Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

Best Papers. F. Fusco

Best Papers. F. Fusco Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical

More information

2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment

2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous

More information

External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer

External Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand

More information